ClinicalTrials.gg
TerminatedNCT05207371Updated Sep 3, 2026

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

A Phase 1/2 interventional study of Biological in Cell Therapy and NSCLC, sponsored by GAIA BioMedicine Inc.. Terminated at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by GAIA BioMedicine Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Decision based on the development company's development policy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

Phase I Part :

Confirm the safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer, and decide recommended dose for Phase II.

Phase II Part :

Explore the efficacy and safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer at the recommended dose of GAIA-102 decided in the Phase I part.

Read the detailed description

Phase I Part :

The GAIA-102 cohort (Level A1\~A3) and the GAIA-102 + Pembrolizumab cohort (Level B1\~B3) will be implemented in a 3 + 3 design. First, start from Level A1 and set the DLT evaluation period until Day 28 of Cycle 1, and confirm the safety up to Cycle 1_Day 28 of Level A1. After that, Level A2 and Level B1 will be started in parallel. After that, unless MTD is recognized, the safety at each level will be confirmed in sequence, and the recommended doses of Phase II part will be determined.

Phase II Part :

At the recommended number of doses confirmed in Phase I Part, 20 patients will be administered up to 3 cycles, and the safety and efficacy of GAIA-102 alone or with pembrolizumab will be evaluated by ORR.

02

Conditions studied

  • Cell Therapy
  • NSCLC
03

In context

Lead sponsor

This is the only study on the registry with GAIA BioMedicine Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have been confirmed to have NSCLC by histological or cytological examination
  2. Patients with performance status (PS) 0-1 at the time of obtaining consent
  3. Patients aged 20 years or older at the time of obtaining consent

Exclusion criteria

Exclusion Criteria:

  1. Patients with symptomatological cranial nerve system . If treatment for cranial nerve system metastasis has already been performed and the neurologically recovered state has been maintained for 2 weeks or more before registration, registration is possible.
  2. Patients diagnosed with cancerous meningitis
  3. Patients who received hematopoietic stem cell transplantation
  4. Patients with active disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    GAIA-102 alone

    GAIA-102: 1 vial (2 x 10\^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks.

    Biological: Biological

  • Experimental
    GAIA-102 with Pembrolizumab

    GAIA-102: 1 vial (2 x 10\^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks. Pembrolizumab:200 mg Administer on Day 1.

    Biological: Biological

Interventions

  • BiologicalBiological

    Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)

This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Phase I part

    Dose Limiting Toxicity

    Time frame: Cycle 1 (Cycle period is 28 days)

  2. Phase II part

    Objective Response Rate (%)

    Time frame: Week 26

Secondary outcomes

  1. Phase I part

    * Objective Response Rate * Disease Control Rate

    Time frame: Week 26

  2. Phase I part

    * Progression-free Survival * Overall Survival

    Time frame: 2 year

  3. Phase II part

    * Progression-free Survival * Overall Survival

    Time frame: 2 year

07

Study locations

3 sites
  • Kyushu University Hospital
    Fukuoka, Fukuoka 812-8582, Japan
  • Kitakyushu Municipal Medical Center
    Kitakyushu, Fukuoka 802-8561, Japan
  • Kurume University Hospital
    Kurume, Fukuoka 830-0011, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Sep 2024, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Jan 26, 2022
StartActual
Dec 1, 2021
Primary completionActual
Sep 1, 2024
CompletionActual
Mar 6, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05207371
Lead sponsor
GAIA BioMedicine Inc.
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
Dec 1, 2021
Primary completion
Sep 1, 2024
Completion
Mar 6, 2026
Last update
Sep 3, 2026

Study contacts

Yoshikazu Yonemitsu, MD, PhD
study director · Graduate School of Pharmaceutical Sciences, Kyushu University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Biological Products

Start the discussion